Skeletal maturity was not accelerated by treatment with recombinant growth hormone ( hGH ) .
BACKGROUND Turner syndrome ( TS ) affects about one in 1500 to 2500 live-born females .
One of the most prevalent and salient features of the syndrome is extremely short stature .
Untreated women are approximately 20 to 21 cm shorter than normal women within their respective population s. Recombinant human growth hormone ( hGH ) has been used to increase growth and final height in girls who have Turner syndrome .
OBJECTIVES To assess the effects of recombinant growth hormone in children and adolescents with TS .
Treatment with two growth hormone regimens in girls with Turner syndrome: final height results. Dutch Growth Hormone Working Group.
In 1987 a multicentre trial of recombinant human growth hormone ( GH ) was started in girls with Turner syndrome . Fifty-four patients were r and omly assigned to receive GH , 8 IU/m2 3 times/week ( group 1 ) , or 4 IU/m2 6 times/week ( group 2 ) . In addition , the 35 patients older than 12 years received ethinyloestradiol , 100 ng/kg body weight/day , and after 2 years GH therapy was increased to 6 IU/m2 6 times/week . Recombinant human GH treatment was stopped when the height increment during the previous 6 months of treatment was less than 0.5 cm . Treatment has so far been stopped in 48 patients : treatment was stopped early in 2 patients due to lack of motivation , 1 patient died suddenly and the treatment protocol was completed in 45 patients . The last height measurement obtained , which was considered as ( near ) final height , was 152.3 + /- 5.3 cm ( mean + /- SD ) in these patients , which is higher ( p < 0.001 ) than the adult height of 147.0 + /- 6.3 cm reported in 63 untreated adult Dutch patients with Turner syndrome . No differences in outcome were found between the two dose regimens
Skeletal maturity was not accelerated by treatment with recombinant growth hormone ( hGH ) .
BACKGROUND Turner syndrome ( TS ) affects about one in 1500 to 2500 live-born females .
One of the most prevalent and salient features of the syndrome is extremely short stature .
Untreated women are approximately 20 to 21 cm shorter than normal women within their respective population s. Recombinant human growth hormone ( hGH ) has been used to increase growth and final height in girls who have Turner syndrome .
OBJECTIVES To assess the effects of recombinant growth hormone in children and adolescents with TS .